A tale of two tumours and a plea for progress.
Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
Rosalie
R
Fisher
Paul
P
Cahalin
Martin
M
Gore
James
J
Larkin
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D000074324:Ipilimumab; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib; D055815:Young Adult
D000911:Antibodies, Monoclonal; D007211:Indoles; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf